Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ROBO1 CAR-NK cells (Asclepius Technology Group)
- Development stage
- Unknown
- Lead developer
- Asclepius Technology Group
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ROBO1 CAR-NK cells are an investigational cell therapy consisting of natural killer (NK) cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the Roundabout homolog 1 (ROBO1) protein. ROBO1 is a cell surface receptor involved in axon guidance and cell migration that is frequently overexpressed in various solid tumors, including pancreatic, lung, and liver cancers, while maintaining limited expression in normal tissues. By targeting ROBO1, these CAR-NK cells are designed to selectively recognize and eliminate tumor cells through direct cytotoxicity. Developed by Asclepius Technology Company Group (Suzhou) Co., Ltd., this therapy is currently being evaluated in Phase 1/2 clinical trials for its safety and efficacy in patients with advanced ROBO1-positive solid tumors.
- Other names
- anti-ROBO1 CAR-NK cellsanti-ROBO-1 CAR-NK cellsanti-ROBO 1 CAR-NK cellsROBO1-specific CAR-NK cellsROBO-1-specific CAR-NK cellsROBO 1-specific CAR-NK cells
02
Targets
ROBO1 (Roundabout guidance receptor 1)
Beyond the preview
Go deeper on ROBO1 CAR-NK cells (Asclepius Technology Group).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ROBO1 CAR-NK cells (Asclepius Technology Group).